Quoin Pharmaceuticals $50M Private Placement
Analysis based on 6 articles · First reported Aug 28, 2026 · Last updated Aug 28, 2026
The private placement provides Quoin Pharmaceuticals with up to $50 million in funding, extending its cash runway into the second half of 2029 and supporting clinical development. This financing is likely to be viewed positively by investors, potentially supporting the company's stock price and reducing near-term dilution concerns.
Quoin Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced on August 28, 2026 that it entered into a securities purchase agreement with healthcare-focused institutional investors to raise up to approximately $50.0 million in gross proceeds. The financing includes initial upfront funding of approximately $30.8 million and up to an additional $19.2 million upon the cash exercise of ordinary warrants. The company will issue 6,305,300 American Depositary Shares (ADSs) and accompanying ordinary warrants at a combined purchase price of $4.88 per ADS and warrant. The warrants have an exercise price of $6.10 per ADS and expire five years from closing or 30 days after the primary endpoint is met in the company's clinical trial CL-QRX003-004 for Netherton Syndrome. The private placement is expected to close on or about August 31, 2026. Proceeds will be used for general corporate purposes, including R&D and completion of clinical development of QRX003. The company expects the net proceeds to fund operations into the second half of 2029. Leerink Partners acted as lead placement agent, with BTIG and Lake Street Capital Markets as co-placement agents. The company has agreed to file a registration statement with the SEC for the resale of the securities.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard